Penumbra Inc (PEN) Expected to Post Earnings of -$0.01 Per Share
Wall Street brokerages expect Penumbra Inc (NYSE:PEN) to announce ($0.01) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Penumbra’s earnings. The lowest EPS estimate is ($0.04) and the highest is $0.01. Penumbra posted earnings of ($0.08) per share during the same quarter last year, which indicates a positive year over year growth rate of 87.5%. The business is scheduled to announce its next quarterly earnings results on Tuesday, February 27th.
On average, analysts expect that Penumbra will report full-year earnings of ($0.15) per share for the current fiscal year, with EPS estimates ranging from ($0.17) to ($0.13). For the next year, analysts anticipate that the firm will post earnings of $0.05 per share, with EPS estimates ranging from $0.01 to $0.11. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Penumbra.
Penumbra (NYSE:PEN) last issued its earnings results on Tuesday, November 7th. The company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.07. The firm had revenue of $83.90 million during the quarter, compared to analyst estimates of $79.17 million. Penumbra had a negative net margin of 2.19% and a negative return on equity of 1.95%. The company’s quarterly revenue was up 24.9% on a year-over-year basis. During the same quarter last year, the business earned ($0.04) earnings per share.
Penumbra (NYSE:PEN) opened at $94.90 on Wednesday. Penumbra has a 1 year low of $62.43 and a 1 year high of $116.35.
In related news, insider Arani Bose sold 16,452 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $105.89, for a total value of $1,742,102.28. Following the sale, the insider now directly owns 728,680 shares of the company’s stock, valued at $77,159,925.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Sridhar Kosaraju sold 6,026 shares of the firm’s stock in a transaction that occurred on Tuesday, November 28th. The shares were sold at an average price of $103.83, for a total transaction of $625,679.58. The disclosure for this sale can be found here. Insiders sold 301,079 shares of company stock valued at $31,150,834 over the last 90 days. 13.50% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC raised its stake in shares of Penumbra by 1.2% during the second quarter. FMR LLC now owns 5,042,974 shares of the company’s stock worth $442,521,000 after acquiring an additional 57,801 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Penumbra by 2.3% during the second quarter. Vanguard Group Inc. now owns 2,165,995 shares of the company’s stock worth $190,066,000 after acquiring an additional 47,768 shares in the last quarter. BlackRock Inc. raised its stake in shares of Penumbra by 4.7% during the second quarter. BlackRock Inc. now owns 1,815,299 shares of the company’s stock worth $159,294,000 after acquiring an additional 81,981 shares in the last quarter. Lord Abbett & CO. LLC raised its stake in shares of Penumbra by 5.1% during the second quarter. Lord Abbett & CO. LLC now owns 1,093,621 shares of the company’s stock worth $95,965,000 after acquiring an additional 53,109 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Penumbra by 13.2% during the second quarter. State Street Corp now owns 579,911 shares of the company’s stock worth $50,887,000 after acquiring an additional 67,441 shares in the last quarter. 71.71% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This article was reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/13/penumbra-inc-pen-expected-to-post-earnings-of-0-01-per-share.html.
Penumbra Company Profile
Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.